



THE ABS CAPACITY DEVELOPMENT INITIATIVE

l'initiative de renforcement des capacites pour l'**APA**

Consideration Digital Sequence Information in the CBD and other UN-fora

Global Webinar 18 April 2023

The ABS Initiative is funded by

Federal Ministry for Economic Cooperation and Development





Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizza

Swiss Confederation

Federal Department of Economic Affairs, Education and Research EAER State Secretariat for Economic Affairs SECO and implemented by



Agenda

Welcome by South Africa & Norway Partnership			
Overview			
Stock-taking on DSI-decisions and negotiations in international fora	Hartmut Meyer		
Reflection panel with Q&A			
Kick-off exchange among panelists	Timothy Hodges Margo Bagley Daniel Kachelriess Suerie Moon Daniele Manzella		
Questions from the Chat			
Further announcements (ABS Initiative)			
Closing remarks (ABS Initiative)			



Welcome

• Gaute Voigt-Hanssen Ministry of Climate and Environment, Norway

• Simon Malete

Department of Forestry, Fisheries and the Environment, South Africa




Stock-taking on DSI-decisions and negotiations in international fora

• Hartmut Meyer

ABS Capacity Development Initiative, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)

ABS Capacity Development Initiative



ABS Initiative working directly in ACP countries

ABS Initiative working in the context of German bilateral development cooperation in ACP countries

ABS Initiative advising German bilateral development cooperation on ABS outside of ACP

ABS Capacity Development Initiative

DSI-activities in the CBD informal process

- DSI Introductory Guide (Aug 2019)
- Studies: Fairness, equity and efficiency for CBD / NP
 incl. case studies (Nov 2021); national approaches to DSI (Feb 2022)
- Video DSI Simply Explained (Dec 2020)
- 10 Webinars (with SCBD, AUC) on the outcomes of the formal DSI process, the role of IPLC, DSI capacity development, commercial uses of DSI (Dec 2020 Jul 2022)
- **1st Global DSI Dialogue** identifying five options for DSI benefit-sharing and points for consideration with regards to assessing them (Nov 2019)
- 2nd Global DSI Dialogue describing the convergences and remaining divergences with regard to DSI benefit-sharing options (Jun – Jul 2021)
- Informal Global DSI Retreat discussing main features of DSI benefit-sharing before COP 15 (Nov 2022)



International DSI Process

CBD / Nagoya Protocol

- COP 13 2016: the big "DSI bang" with decision on information gathering and studies on general issues
- COP 14 2018: negotiations with decision on "how to address DSI in the context of the post-2020 GBF" and studies on specific topics

CBD

- AHTEG 2 2020: options for operational terms and identification of key areas for capacity-building
- COP 15 2022: Decision on multilateral system for DSI benefit-sharing

Other Fora

- WIPO standard on DSI in patent applications
- UNCLOS BBNJ agreement on marine GR and DSI benefit-sharing
- WHO Pandemic Treaty (negotiations on pathogene and genomic data benefitsharing)
- FAO ITPGRFA and CGRFA (studies, proposal for inclusion of DSI in the SMTA of the IT)

International DSI Process

CBD / Nagoya Protocol

- COP 13 2016: the big "DSI bang" with decision on information gathering and studies on general issues
- COP 14 2018: negotiations with decision on "how to address DSI in the context of the post-2020 GBF" and studies on specific topics

CBD THE LAW Organization

ITPGRE

- AHTEG 2 2020: options for operational terms and identification of key areas for capacity-building
- COP 15 2022: Decision on multilateral system for DSI benefit-sharing

Other Fora

- WIPO standard on DSI in patent applications
- UNCLOS BBNJ agreement on marine GR and DSI benefit-sharing
- WHO Pandemic Treaty (negotiations on pathogene and genomic data benefitsharing)
- FAO ITPGRFA and CGRFA (studies, proposal for inclusion of DSI in the SMTA of the IT, further work on DSI until the 10th Meeting of the IT Governing Body in 2023)

DSI-Agreements





CBD, UNCLOS & WHO on objectives & definition of DSI

CBD DSI	UNCLOS BBNJ	WHO CA+
 <u>No objective</u> but agreement on: fair and equitable sharing of benefits arising from the use of DSI benefit-sharing should support conservation and sustainable use of biological diversity and benefit indigenous peoples and local communities 	 fair and equitable sharing of benefits arising from activities with respect to MGR and DSI capacity building and development generation of knowledge, scientific understanding and technological innovation development and transfer of marine technology 	 prevent pandemics, save lives, reduce disease burden and protect livelihoods multilateral, fair, equitable and timely system for sharing of pathogens with pandemic potential and genomic sequences, and benefits arising therefrom
No definition of DSI	No definition of DSI	"genomic sequences" means the order of nucleotides identified in a molecule of DNA or RNA. They contain the full genetic information that determines the biological characteristics of an organism or a virus;







CBD, UNCLOS & WHO on sharing of non-monetary and monetary benefits




CBD DSI	UNCLOS BBNJ	WHO CA+
Non monetary BS: to be discussed	 Governed by ABS Committee Access to samples, DSI and scientific data Transfer of marine technology Capacity-building, including by financing research programmes and partnerships Increased technical and scientific cooperation 	 Governed by Standard MTA access by WHO to 20% of the production of pandemic-related products, as diagnostics, vaccines etc 10% as a donation and 10% at affordable prices to WHO distribution, in particular to developing countries, according to public health risk and need and national plans that identify priority populations
Monetary BS: to be discussed	 Contributions by Member States Milestone payment contribution based on commercialization of products, including percentages of revenues from product sales 	Not mentioned








CBD DSI	UNCLOS BBNJ	WHO CA+
 Establishment of a global fund Details to be discussed 	 Establishment of a funding mechanism, incl. a special fund receiving monetary benefits 	No provisions
 Open-ended working group on DSI benefit-sharing and advisory committee on resource mobilization make recommendations on modalities of DSI fund until COP 16 in late 2024 	 Agreement still needs to be adopted Entry into force after 60th ratification 	 Agreement under negotiation Adoption at 77th World Health Assembly, May 2024 Entry into force after 30th ratification












- Margo Bagley Emory University School of Law, Atlanta
- Daniel Kachelriess Expert on oceans, fisheries, wildlife law and policy, Vienna
- Suerie Moon Graduate Institute of International and Development Studies, Geneva
- Daniele Manzella Food and Agriculture Organization, Rome

Facilitation: **Timothy Hodges**, *Mc Gill University, Montreal*

Evaluation and further reading

- Before you leave, please help us improving our work and participate in the short evaluation of this webinar
- We digested a collection of useful newcomer / expert material dealing with DSI in the CBD and other for a which will be shared with participants via e-mail.







Thank you!



Further information can be found on our website: <u>www.abs-biotrade.info</u>

ABS Capacity Development Initiative Division Climate Change, Environment & Infrastructure GloBe - Department Sector and Global Programmes Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH Postfach /P.O. Box 5180 65726 Eschborn Germany

The ABS Initiative is funded by



NORWEGIAN MINISTRY OF FOREIGN AFFAIRS



Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra


Swiss Confederation

Federal Department of Economic Affairs, Education and Research EAER State Secretariat for Economic Affairs SECO

and implemented by







Pathogen- and Benefit-Sharing in the Pandemic Instrument

Informal, intersessional briefing on Access and benefit sharing in the context of strengthening pandemic prevention, preparedness and response

22 March 2023 Suerie Moon, MPA PhD Co-Director, Global Health Centre & Professor of Practice, International Relations & Political Science Graduate Institute of International and Development Studies, Geneva



GRADUATE

ABS: Lessons from Covid-19, Ebola & Zika


- 15 million sequences shared
 → informal scientific norms for sharing
- Preference for data ownership protections (Table 1)
- Increased sequencing capacity, but more needed •
- Inadequate arrangements for benefit-sharing
- No clear obligations for sharing pathogens, GSD or benefits
- Recent political/legal progress: CBD & BBNJ

Table 1. Proportion of Countries within an Income Level Submitting any Sequences, January 1, 2020 – March 18, 2023

	GISAID	GenBank
Total	183/191	110/191
	(95.81%)	(57.59%)
High Income	57/58	42/58
	(98.27%)	(72.41%)
Upper Middle	50/53	32/53
	(94.34%)	(60.38%)
Lower Middle	51/52	25/49
	(98.08%)	(51.02%)
Low Income	25/28	11/28
	(89.29%)	(39.29%)

Source: With thanks to Anna Bezruki (Georgetown University) for data & analysis







GENEVA GRADUATE INSTITUTE GLOBAL HEALTH CENTRE

Pathogen- and Benefit-sharing in the CA+

- Useful
 - Inclusion of pathogen and benefit-sharing on equal footing; open science approach; obligation for all MS to share samples, GSD <u>and</u> benefits; some limits on IP
- Areas for improvement:
 - Benefits to include possibility of technology transfer (not only 20% product sales/donation to WHO)
 - Member State **Benefits Committee** could negotiate benefits for commercial use case-by-case, not leave options to sample/data-user only
 - Limits on ability to claim IP very narrow
 - More clarity and emphasis on transparency of system, capacitybuilding, and financing
 - Scope to include animal, plant, environmental pathogens (OneHealth)

Source: For further discussion, see Rizk A, Strobejko A, Burci GL, Moon S. (2022) https://repository.graduateinstitute.ch/record/301010



Non-Commercial Use Samples Benefits WHO, Co-Authorship MEMBE SMTA1 International Government SMTA2 R STATE Lab Network Collaboration SMTA2 Agencies Information Surveillance (e.g., biohubs, MEMBE SMTA1 Capacity CAPACITY STRENGTHENING WHO CCs) STATE Information Building SMTA2 GSD Commercial Uso **Benefits** Commitment SMTA3 to Share MEMBE R&D DSA1 WHO Stockpiles International Samples & Industry Databases for GSD GSD SMTA3 Tech Transfer, - Vaccines MEMBE SMTA3 DSA1 (e.g., GISAID, IP, Know-how for R STATE - Drugs INSDC) Local Production Diagnostics Royalties FINANCING MEMBE R STATE MEMBE MEMBE PHILANTHROP R STATE V

Legally-Binding Member State Commitments (Pandemic Instrument and/or IHR)

Commitment to Transparency

Commitment to Finance and Strengthen Capacity

Commitment to Share **Benefits**